Breaks Categories: News

WednesdayFeb 03, 2021 11:06 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Signs Production Agreement with Applied Pharmaceutical Innovation

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has signed an agreement with Applied Pharmaceutical Innovation. A not-for-profit institution at the University of Alberta, Applied supports translational drug development for industry and innovators. XPhyto’s psychedelic pharmaceutical production agreement calls for the synthesis of pharmaceutical-grade psychedelic compounds and the development of the standard operating procedures required to obtain regulatory approval for the commercial production process. As part of its psychedelic pharmaceutical program, XPhyto needs industrial-scale production of standardized active pharmaceutical ingredients. This agreement is part of that strategic…

Continue Reading

WednesdayFeb 03, 2021 10:39 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Completes New Company Registration for Class 1 NPN

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp and mushroom products, announced that it has completed its application for new company registration with the Natural and Non-prescription Health Products Directorate (“NNHPD”) and subsequently has received its company code. As a result, Pure Extracts can now submit an application for a Class 1 Natural Product Number (“NPN”) for a functional mushroom product. PULL anticipates this will be the first of several NPN applications it submits in 2021. The applications are part of Pure Extracts strategic plan to sell functional mushroom wellness products through…

Continue Reading

WednesdayJan 27, 2021 1:52 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) US Shares Gain DTC Eligibility

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, this morning announced that its common shares on the OTC Market under the symbol "PRXTF" are now eligible for electronic clearing and settlement through The Depository Trust Company ("DTC"). “DTC eligibility is a major step forward in increasing liquidity, broadening our shareholder base and building a strong presence for our company within the US capital markets sphere. This is an important step in amplifying our story to a wider audience,” Pure Extracts CEO Ben Nikolaevsky stated in the news release. To view…

Continue Reading

TuesdayJan 26, 2021 10:27 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Announces Biomass Purchase Agreements to Scale-Up Extract Production

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has entered into its first initial substantial biomass purchase agreements; the agreements are designed to support an increase in the company’s production of THC and CBD oil extracts. Executed with a large Canadian Licensed Producer, one purchase agreement outlines Pure Extracts’ intent to purchase 220 kgs of high-potency THC cannabis dried flower; the company also agreed to purchase approximately 1,000 kgs of high-potency CBD biomass from a top Western Canada cultivator. The company plans to use the cannabis to produce full-spectrum (“FSO”) THC…

Continue Reading

MondayJan 25, 2021 11:25 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Opens New CRTCE Clinic to Provide Ketamine Treatment for Adults with Depression

Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions, has opened its third Canadian Rapid Treatment Center of Excellence (“CRTCE”) clinic. Champignon chairman and CEO Roger McIntyre announced the opening of the center; the announcement noted that the clinics — the other two are located in Mississauga and Toronto — are focused on the treatment of depression and suicide through novel ketamine therapy treatment. The company noted in the announcement that more than 20 clinical trials have been conducted that demonstrate the effectiveness of ketamine and…

Continue Reading

ThursdayJan 21, 2021 3:34 pm

PsychedelicNewsBreaks – Following a Year of Success, Psychedelics Could Emerge Large in 2021

The year 2020 was a great year for psychedelics; more than two dozen companies focusing on psychedelics in some manner became publicly listed. That success certainly seems to have sparked interest in what the sector will see in 2021. A recent Benzinga article, titled “What Will the Psychedelics Space Look Like in 2021? Experts Weigh In” noted that as psychedelics grow closer to receiving federal legalization, scientific, regulatory and corporate developments are almost daily news. Experts in the field are looking for new clinical and R&D initiatives to emerge, investment opportunities to increase, and public acceptance to expand. In addition,…

Continue Reading

ThursdayJan 14, 2021 9:25 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Announces Upcoming Study on Psilocybin-Based Nasal Gel, Oral Tablets and Capsules

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has released the timetable and milestones for a proprietary study. The study is designed to evaluate the formulation, manufacturing and clinical bioavailability of psilocybin-based, rapid-onset active treatments for a nasal gel as well as oral tablets and capsules that will be used as an investigational product. PULL anticipates that the study will be conducted by Dr. Alexander MacGregor at the Toronto Institute of Pharmaceutical Technology (“TIPT”); MacGregor is a scientific advisor for Pure Extracts. During the study, the company will be evaluating several…

Continue Reading

MondayJan 11, 2021 11:47 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces New CFO, General Counsel

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) chairman and CEO Roger McIntyre today announced the company's appointment of Stephen R. Brooks as its new chief financial officer and Peter Rizakos as the firm's new general counsel. According to the update, these appointments complete the company's new top management team put into place by Dr. McIntyre and the Champignon Board of Directors.  "These new management additions ready us for the future where the Company's clinical products and services will help meet the enormous public need that is creating significant public demand for improved, ketamine-based treatments that are capable of rapid response…

Continue Reading

MondayJan 11, 2021 11:19 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Strategic Partnership with Kernel

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel (“Kernel”) to leverage its innovative technology, Kernel Flow (“Flow”), for its upcoming sponsored clinical work. “Access to Kernel’s innovative Flow technology adds another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction. Currently, clinical investigators rely on limited subjective information from patients. The ability to collect quantitative data from our sponsored drug development programs is potentially…

Continue Reading

FridayJan 08, 2021 11:31 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Article Outlining Future Potential in Novel Agents for Bipolar Disorders

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) today announced the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article, “Bipolar Disorders” is published in The Lancet – one of the world's best-known and most reputable scientific journals in medicine. According to the update, the article contributes to The Lancet 's collection of peer-reviewed seminars and provides a "state-of-the-art overview of bipolar disorders, covering epidemiology, parthenogenesis, diagnosis, treatment, and prevention, while highlighting relevant clinical controversies." "The availability of so-called rapid-onset treatments (e.g., ketamine) and treatments that could mitigate suicidality is crucial to clinical settings,"…

Continue Reading